Filed Pursuant to Rule 424(b)(5)
Registration No. 333-253532
PROSPECTUS SUPPLEMENT
(To Prospectus dated February 25, 2021)
COMMON STOCK
We have entered into separate sales agency financing agreements with each of J.P. Morgan Securities LLC, Barclays Capital Inc., BNP Paribas Securities Corp., BofA Securities, Inc., BTIG, LLC, Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, Jefferies LLC, Mizuho Securities USA LLC, Morgan Stanley & Co. LLC, RBC Capital Markets, LLC, Scotia Capital (USA) Inc., TD Securities (USA) LLC, Truist Securities, Inc. and Wells Fargo Securities, LLC (collectively, the sales agents) and, as applicable, the forward purchasers (as described below), dated January 17, 2023, relating to issuances, offers and sales of shares of our common stock pursuant to our fifth continuous equity program. We refer to these agreements, collectively, as the sales agency financing agreements. The sales agency financing agreements amend and restate the sales agency financing agreements that we entered into with certain of the sales agents on May 6, 2019, which we refer to herein as the original sales agency financing agreements, to, among other things, include BNP Paribas Securities Corp., Mizuho Securities USA LLC and Scotia Capital (USA) Inc. as additional sales agents under our fifth continuous equity program. We may offer and sell up to $1,000,000,000 of our common stock (in the aggregate, including the amount sold pursuant to the original sales agency financing agreements) from time to time through any of the sales agents (acting in their capacity as sales agents or as forward sellers, as described below). The shares of common stock offered for sale under the sales agency financing agreements will be offered at market prices prevailing at the time of sale.
The sales agency financing agreements provide that, in addition to the issuance and sale of shares of our common stock by us through the sales agents, we also may enter into forward sale agreements under separate master forward sale agreements and related supplemental confirmations between us and each of JPMorgan Chase Bank, N.A., Bank of America, N.A., Barclays Bank PLC, BNP Paribas, Deutsche Bank AG, London Branch, Goldman Sachs & Co. LLC, Jefferies LLC, Mizuho Markets Americas LLC, Morgan Stanley & Co. LLC, Royal Bank of Canada, The Bank of Nova Scotia, The Toronto-Dominion Bank, Truist Bank and Wells Fargo Bank, National Association (or their respective affiliates). We refer to these agreements, collectively, as the forward sale agreements, and we refer to these entities, when acting in this capacity, individually as a forward purchaser and collectively as forward purchasers. In connection with each particular forward sale agreement, the relevant forward purchaser will, at our request, borrow from third parties and, through the relevant sales agent, sell a number of shares of our common stock equal to the number of shares of our common stock underlying the particular forward sale agreement. We refer to the sales agents, when acting as agents for forward purchasers, as forward sellers. In no event will the aggregate number of shares of our common stock sold through the sales agents, whether as an agent for us or as a forward seller, under the sales agency financing agreements (together with the aggregate number of shares of our common stock sold pursuant to the original sales agency financing agreements) and under any forward sale agreements (together with the aggregate number of shares of our common stock sold pursuant to the original master forward sale agreements (as described below)), have an aggregate sales price in excess of $1,000,000,000.
As of the date of this prospectus supplement, we have sold shares of common stock having an aggregate offering price of $294,039,111.66 under the original sales agency financing agreements and the separate master forward sale agreements, dated May 6, 2019, that we entered into with certain of the forward purchasers, which we refer to as the original master forward sale agreements, and shares of common stock having an aggregate offering price of $705,960,888.34 remain unsold under our fifth continuous equity program. This prospectus supplement, together with the accompanying prospectus, supersedes the prospectus supplement dated February 25, 2021 relating to the original sales agency financing agreements and original master forward sale agreements.
We will not initially receive any proceeds from the sale of borrowed shares of our common stock by a forward seller. We expect to fully physically settle each particular forward sale agreement with the relevant forward purchaser on one or more dates specified by us on or prior to the maturity date of that particular forward sale agreement, in which case we will expect to receive aggregate net cash proceeds at settlement equal to the number of shares underlying the particular forward sale agreement multiplied by the relevant forward sale price. However, we may also elect to cash settle or net share settle a particular forward sale agreement, in which case we may not receive any proceeds (in the case of cash settlement) or will not receive any proceeds (in the case of net share settlement), and we may owe cash (in the case of cash settlement) or shares of common stock (in the case of net share settlement) to the relevant forward purchaser.
The sales agents will offer our common stock in “at the market” offerings or by other methods described in “Plan of Distribution.” We will pay each sales agent a commission at a mutually agreed rate that will not exceed, but may be lower than, 1.50% of the sales price of all of the shares of common stock issued by us and sold through it as our sales agent under the relevant sales agency financing agreement. In connection with each forward sale agreement, we will pay the relevant forward seller, in the form of a reduced initial forward sale price under the related forward sale agreement with the related forward purchaser, commissions at a mutually agreed rate that will not exceed, but may be lower than, 1.50% of the sales prices of all borrowed shares of common stock sold during the applicable forward hedge selling period by it as a forward seller.
Our common stock is listed on the New York Stock Exchange under the symbol “AVB.” On January 13, 2023, the closing price of our common stock on the New York Stock Exchange was $167.85 per share.
Investing in our common stock involves risks. See “Risk Factors” beginning on page S-3 of this prospectus supplement and page 1 of the accompanying prospectus. The Securities and Exchange Commission and state securities regulators have not approved or disapproved these securities, or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
| J.P. Morgan | | | Barclays | | | BNP PARIBAS | |
| BofA Securities | | | BTIG | | | Deutsche Bank Securities | |
| Goldman Sachs & Co. LLC | | | Jefferies | | | Mizuho | |
| Morgan Stanley | | | RBC Capital Markets | | | Scotiabank | |
| TD Securities | | | Truist Securities | | | Wells Fargo Securities | |
The date of this prospectus supplement is January 17, 2023.